Algernon Pharmaceuticals Completes Name Change to Algernon Health

Rhea-AI Summary

Algernon Health (OTCQB: AGNPF) completed its name change from Algernon Pharmaceuticals and will begin trading under the new name on the CSE at market open on October 20, 2025 while retaining the same ticker symbol. The common shares received a new CUSIP 01559C106 and ISIN CA01559C1068; no shareholder action is required.

The company said it will focus on the Alzheimer’s disease diagnostic market by establishing neuroimaging clinics using U.S. FDA-cleared brain-specific PET scanners. Algernon signed a definitive equipment order and financing agreement with Catalyst MedTech for four CareMiBrain PET systems, a non-dilutive deal valued at > CDN $4 million, plus terms to acquire six additional systems on an adjusted-cost basis.

Positive

• Non-dilutive equipment deal valued at > CDN $4 million
• Four CareMiBrain PET systems contracted for four planned clinics
• PET scans are covered by Medicare, Medicaid, and private insurance
• New CUSIP/ISIN assigned (01559C106 / CA01559C1068) before Oct 20, 2025

Negative

• Clinic rollout carries execution risk; commercial revenue not disclosed
• Additional six systems subject to adjusted-cost terms, implying possible future capital commitments

VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has completed its previously announced name change to Algernon Health Inc. The Company’s common shares will begin trading under the new name on the CSE at market-open on Monday, October 20, 2025. The common shares will trade under the new name with a new CUSIP number, but the stock symbol will remain the same.

In connection with the name change, the following new CUSIP (01559C106) and ISIN (CA01559C1068) numbers have been assigned to the common shares of the Company. No action is required to be taken by the shareholders with respect to the name change.

This name changeover on the Company’s website, in its digital marketing and social media materials and links, and in its URL and company email addresses will be changed on a rolling basis over a short window of time, as files and platforms are updated and refreshed across various networks and platforms.

The name change reflects the Company’s recent announcement that it will be focusing on the Alzheimer’s Disease (AD) diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. FDA-cleared, optimized brain-specific Positron Emission Tomography (PET) scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared to standard PET/CT machines currently in operation globally. The PET scans are covered by Medicare, Medicaid, and private insurance.

The Company recently announced that it had signed a definitive equipment order and financing agreement with Catalyst MedTech (“Catalyst”) for the provision of four Oncovision CareMiBrain™ brain-specific, Positron Emission Tomography (PET) scanner systems to be utilized in four planned Algernon neuroimaging medical clinics. This represents a non-dilutive deal value of over CDN $4 million and includes an agreement to acquire an additional six systems for the establishment of additional clinics, on an adjusted cost basis.

“Our change in name is an important step in the execution of our new health care initiative to establish and operate dedicated neuroimaging clinics for the early-stage detection of Alzheimer’s disease,” said Christopher J. Moreau, CEO of Algernon Health. “It underscores our commitment as an evolving, consumer facing brand providing health care solutions to patients in need.”

Algernon continues to be the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil.

Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.

About Algernon Health

Algernon Health is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

FAQ

When will Algernon Health (AGNPF) start trading under its new name?

Algernon Health common shares begin trading on the CSE under the new name at market open on October 20, 2025.

Will AGNPF’s stock symbol change after the name change?

No; the stock symbol remains AGNPF, though the company received a new CUSIP and ISIN.

What equipment agreement did Algernon Health announce for its neuroimaging clinics?

Algernon signed a definitive order and financing agreement with Catalyst MedTech for four Oncovision CareMiBrain PET systems.

How much is the Catalyst MedTech equipment deal worth to Algernon Health?

The agreement represents a non-dilutive deal value of over CDN $4 million and includes terms for six additional systems.

Will Algernon Health’s PET scans be covered by insurance for patients?

Yes; the company states the brain-specific PET scans are covered by Medicare, Medicaid, and private insurance.

Do shareholders need to take any action for Algernon Health’s name change (AGNPF)?

No action is required by shareholders; new CUSIP and ISIN were assigned and trading continues under the same symbol.